Adaptive Biotechnologies (NASDAQ:ADPT) and Ocugen (NASDAQ:OCGN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, profitability, analyst recommendations, risk and valuation.
Institutional & Insider Ownership
80.8% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 8.5% of Ocugen shares are owned by institutional investors. 22.2% of Adaptive Biotechnologies shares are owned by company insiders. Comparatively, 3.5% of Ocugen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Adaptive Biotechnologies and Ocugen, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Adaptive Biotechnologies | 0 | 2 | 4 | 0 | 2.67 |
Ocugen | 0 | 1 | 3 | 0 | 2.75 |
Adaptive Biotechnologies presently has a consensus price target of $61.40, indicating a potential upside of 40.57%. Ocugen has a consensus price target of $4.80, indicating a potential downside of 46.49%. Given Adaptive Biotechnologies' higher possible upside, research analysts plainly believe Adaptive Biotechnologies is more favorable than Ocugen.
Earnings & Valuation
This table compares Adaptive Biotechnologies and Ocugen's revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Adaptive Biotechnologies | $85.07 million | 71.48 | $-68,610,000.00 | ($1.01) | -43.25 |
Ocugen | N/A | N/A | $-20,240,000.00 | ($1.48) | -6.06 |
Ocugen has lower revenue, but higher earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Adaptive Biotechnologies has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500. Comparatively, Ocugen has a beta of 3.56, suggesting that its stock price is 256% more volatile than the S&P 500.
Profitability
This table compares Adaptive Biotechnologies and Ocugen's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Adaptive Biotechnologies | -132.32% | -20.15% | -13.09% |
Ocugen | N/A | -47.72% | -30.78% |
Summary
Adaptive Biotechnologies beats Ocugen on 8 of the 13 factors compared between the two stocks.